Dried-leaf Artemisia annua: A practical malaria therapeutic for developing countries?

Pamela J Weathers, Melissa Towler, Ahmed Hassanali, Pierre Lutgen, Patrick Ogwang Engeu
{"title":"Dried-leaf <i>Artemisia annua:</i> A practical malaria therapeutic for developing countries?","authors":"Pamela J Weathers,&nbsp;Melissa Towler,&nbsp;Ahmed Hassanali,&nbsp;Pierre Lutgen,&nbsp;Patrick Ogwang Engeu","doi":"10.5497/wjp.v3.i4.39","DOIUrl":null,"url":null,"abstract":"<p><p>Artemisinin from the plant <i>Artemisia annua (A. annua)</i> L, and used as artemisinin combination therapy (ACT), is the current best therapeutic for treating malaria, a disease that hits children and adults especially in developing countries. Traditionally, <i>A. annua</i> was used by the Chinese as a tea to treat \"fever\". More recently, investigators have shown that tea infusions and oral consumption of the dried leaves of the plant have prophylactic and therapeutic efficacy. The presence of a complex matrix of chemicals within the leaves seems to enhance both the bioavailability and efficacy of artemisinin. Although about 1000-fold less potent than artemisinin in their antiplasmodial activity, these plant chemicals are mainly small molecules that include other artemisinic compounds, terpenes (mainly mono and sesqui), flavonoids, and polyphenolic acids. In addition, polysaccharide constituents of <i>A. annua</i> may enhance bioavailability of artemisinin. Rodent pharmacokinetics showed longer T<sub>1/2</sub> and T<sub>max</sub> and greater C<sub>max</sub> and AUC in <i>Plasmodium chabaudi</i>-infected mice treated with <i>A. annua</i> dried leaves than in healthy mice. Pharmacokinetics of deoxyartemisinin, a liver metabolite of artemisinin, was more inhibited in infected than in healthy mice. In healthy mice, artemisinin serum levels were > 40-fold greater in dried leaf fed mice than those fed with pure artemisinin. Human trial data showed that when delivered as dried leaves, 40-fold less artemisinin was required to obtain a therapeutic response compared to pure artemisinin. ACTs are still unaffordable for many malaria patients, and cost estimates for <i>A. annua</i> dried leaf tablet production are orders of magnitude less than for ACT, despite improvements in the production capacity. Considering that for > 2000 years this plant was used in traditional Chinese medicine for treatment of fever with no apparent appearance of artemisinin drug resistance, the evidence argues for inclusion of affordable <i>A. annua</i> dried leaf tablets into the arsenal of drugs to combat malaria and other artemisinin-susceptible diseases.</p>","PeriodicalId":90768,"journal":{"name":"World journal of pharmacology","volume":"3 4","pages":"39-55"},"PeriodicalIF":0.0000,"publicationDate":"2014-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4323188/pdf/nihms656647.pdf","citationCount":"73","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World journal of pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5497/wjp.v3.i4.39","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 73

Abstract

Artemisinin from the plant Artemisia annua (A. annua) L, and used as artemisinin combination therapy (ACT), is the current best therapeutic for treating malaria, a disease that hits children and adults especially in developing countries. Traditionally, A. annua was used by the Chinese as a tea to treat "fever". More recently, investigators have shown that tea infusions and oral consumption of the dried leaves of the plant have prophylactic and therapeutic efficacy. The presence of a complex matrix of chemicals within the leaves seems to enhance both the bioavailability and efficacy of artemisinin. Although about 1000-fold less potent than artemisinin in their antiplasmodial activity, these plant chemicals are mainly small molecules that include other artemisinic compounds, terpenes (mainly mono and sesqui), flavonoids, and polyphenolic acids. In addition, polysaccharide constituents of A. annua may enhance bioavailability of artemisinin. Rodent pharmacokinetics showed longer T1/2 and Tmax and greater Cmax and AUC in Plasmodium chabaudi-infected mice treated with A. annua dried leaves than in healthy mice. Pharmacokinetics of deoxyartemisinin, a liver metabolite of artemisinin, was more inhibited in infected than in healthy mice. In healthy mice, artemisinin serum levels were > 40-fold greater in dried leaf fed mice than those fed with pure artemisinin. Human trial data showed that when delivered as dried leaves, 40-fold less artemisinin was required to obtain a therapeutic response compared to pure artemisinin. ACTs are still unaffordable for many malaria patients, and cost estimates for A. annua dried leaf tablet production are orders of magnitude less than for ACT, despite improvements in the production capacity. Considering that for > 2000 years this plant was used in traditional Chinese medicine for treatment of fever with no apparent appearance of artemisinin drug resistance, the evidence argues for inclusion of affordable A. annua dried leaf tablets into the arsenal of drugs to combat malaria and other artemisinin-susceptible diseases.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
干叶黄花蒿:发展中国家的实用疟疾治疗药物?
从植物黄花蒿(a . annua) L中提取的青蒿素被用作青蒿素联合疗法(ACT),是目前治疗疟疾的最佳疗法。疟疾是一种影响儿童和成人的疾病,尤其是在发展中国家。传统上,黄花菊被中国人用作治疗“发烧”的茶。最近,研究人员已经证明,茶叶浸泡和口服这种植物的干叶子具有预防和治疗功效。叶子中化学物质的复杂基质的存在似乎提高了青蒿素的生物利用度和功效。尽管这些植物化学物质的抗疟原虫活性比青蒿素低约1000倍,但它们主要是小分子,包括其他青蒿类化合物、萜烯(主要是单萜类和倍萜类)、类黄酮和多酚酸。此外,黄花蒿多糖成分可能提高青蒿素的生物利用度。啮齿动物药代动力学结果显示,与健康小鼠相比,黄花蒿干叶处理的恰布地疟原虫感染小鼠的T1/2和Tmax更长,Cmax和AUC更大。脱氧青蒿素(一种青蒿素的肝脏代谢物)的药代动力学在感染小鼠中比在健康小鼠中受到更大的抑制。在健康小鼠中,用干叶子喂养的小鼠血清中青蒿素水平比用纯青蒿素喂养的小鼠高40倍以上。人体试验数据表明,与纯青蒿素相比,以干叶子形式递送所需的青蒿素可减少40倍以获得治疗反应。许多疟疾患者仍然负担不起以青蒿素为基础的联合疗法,尽管生产能力有所改善,但青蒿素干叶片剂生产的成本估计比以青蒿素为基础的联合疗法低几个数量级。考虑到在超过2000年的时间里,这种植物被用于中医治疗发烧,没有出现明显的青蒿素耐药性,有证据表明,应将负担得起的黄花蒿干叶片纳入防治疟疾和其他青蒿素易感疾病的药物库中。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Natural isothiocyanates of the genus Capparis as potential agonists of apoptosis and antitumor agents: Mechanisms and implications Natural isothiocyanates of the genus Capparis as potential agonists of apoptosis and antitumor drugs In silico insight into Amurensinine - an N-Methyl-D-Aspartate receptor antagonist Commentary: Discussing the antidepressant potential of silymarin Recurrent ciprofloxacin induced hypoglycemia in a non-diabetic patient: A case report
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1